The Pharmaceutical Industry in Figures EFPIA

The Pharmaceutical Industry In Figures Efpia-Free PDF

  • Date:19 Jul 2020
  • Views:7
  • Downloads:0
  • Pages:28
  • Size:7.88 MB

Share Pdf : The Pharmaceutical Industry In Figures Efpia

Download and Preview : The Pharmaceutical Industry In Figures Efpia


Report CopyRight/DMCA Form For : The Pharmaceutical Industry In Figures Efpia


Transcription:

EFPIA Key Data 2018,THE PHARMACEUTICAL INDUSTRY,A KEY ASSET TO SCIENTIFIC AND MEDICAL PROGRESS. Thanks to advances in science and technology the immobility and some cancers can be controlled or. research based pharmaceutical industry is entering even cured with the help of new targeted treatments. an exciting new era in medicines development European citizens can expect not only to live longer. Research methods are evolving and we have many but to live better quality lives Yet major hurdles remain. promising prospects on the horizon from the including Alzheimer s Multiple Sclerosis many cancers. possibilities offered by personalised medicines to and orphan diseases. the potential offered by harnessing the power of,big data The innovative pharmaceutical industry. is driven by and drives medical progress It aims,to turn fundamental research into innovative. treatments that are widely available and accessible. to patients, Already the industry has contributed to significant. improvements in patient well being Today s European. citizens can expect to live up to 30 years longer,than they did a century ago Some major steps in.
biopharmaceutical research complimented by,many smaller steps have allowed for reductions in. mortality for instance from HIV AIDS related causes. and a number of cancers High blood pressure and,cardiovascular diseases can be controlled with. antihypertensive and cholesterol lowering medicines. knee or hip replacements prevent patients from, TOTAL NUMBER OF DEATHS AMONG AIDS CASES IN EUROPE TOTAL EU EEA. 4000 Source HIV AIDS,surveillance in,2928 Europe 2017 WHO. 3000 2616 Regional Office for,2140 Europe European.
1918 1954 Centre for Disease,2000 1690 Prevention and. Control ECDC,907 849 November 2017,2007 2008 2009 2010 2011 2012 2013 2014 2015 2016. THE PHARMACEUTICAL INDUSTRY A KEY ASSET TO THE,EUROPEAN ECONOMY. As well as driving medical progress by researching is a key asset of the European economy It is one of. developing and bringing new medicines that improve Europe s top performing high technology sectors. health and quality of life for patients around the. world the research based pharmaceutical industry,INDUSTRY EFPIA total 2000 2010 2016 2017. Production 127 504 199 400 248 053 258 000 e,Exports 1 2 90 935 276 357 373 333 385 000 e.
Imports 68 841 204 824 278 462 287 000 e,Trade balance 22 094 71 533 94 871 98 000 e. R D expenditure 17 849 27 920 33 949 35 200 e, Employment units 554 186 670 088 747 607 750 000 e. R D employment units 88 397 117 035 112 425 115 000 e. Total pharmaceutical market value,89 449 153 685 199 234 207 000 e. at ex factory prices,Payment for pharmaceuticals, by statutory health insurance systems 76 909 129 464 133 203 137 000 e. ambulatory care only,Values in million unless otherwise stated.
1 Data relate to EU 27 Norway and Switzerland since 2005 EU 15 before 2005 Croatia and Serbia included since 2010 Turkey. included since 2011 Russia included since 2013, 2 Data relating to total exports and total imports include EU 28 intra trade double counting in some cases. Source EFPIA member associations official figures e EFPIA estimate Eurostat EU 28 trade data 2000 2017. EFPIA Key Data 2018,MAIN TRENDS, The research based pharmaceutical industry can Indian markets grew by 11 5 9 4 and 11 0. play a critical role in restoring Europe to growth and respectively compared to an average market. ensuring future competitiveness in an advancing growth of 4 4 for the top 5 European Union. global economy In 2017 it invested an estimated markets and 7 3 for the US market source IQVIA. 35 200 million in R D in Europe It directly employs Institute March 2018. some 750 000 people and generates three to four,In 2017 North America accounted for 48 1 of. times more employment indirectly upstream and,world pharmaceutical sales compared with 22 2. downstream than it does directly However the,for Europe According to IQVIA data MIDAS May.
sector faces real challenges Besides the additional. 2018 64 1 of sales of new medicines launched,regulatory hurdles and escalating R D costs the. during the period 2012 2017 were on the US mar, sector has been severely hit by the impact of fiscal. ket compared with 18 1 on the European mar,austerity measures introduced by governments. ket top 5 markets,across much of Europe since 2010. The fragmentation of the EU pharmaceutical, There is rapid growth in the market and research market has resulted in a lucrative parallel trade.
environment in emerging economies such as This benefits neither social security nor patients. Brazil China and India leading to a gradual and deprives the industry of additional resources. migration of economic and research activities from to fund R D Parallel trade was estimated to. Europe to these fast growing markets During amount to 5 202 million value at ex factory. the period 2013 2017 the Brazilian Chinese and prices in 2016. GEOGRAPHICAL BREAKDOWN BY MAIN MARKETS OF SALES OF NEW MEDICINES LAUNCHED DURING THE. PERIOD 2012 2017,New medicines cover all new,active ingredients marketed. for the first time on the world,market during the period. 64 1 2012 2017,Europe Europe Top 5 comprises,Top 5 Germany France Italy Spain. 7 1 and United Kingdom,Pharmerging comprises,9 2 21 countries ranked by IQVIA. the World as high growth pharmaceutical,Algeria Argentina Bangladesh.
Pharmerging,Brazil Colombia Chile China,Egypt India Indonesia. Kazakhstan Mexico Nigeria,Pakistan Philippines Poland. Russia Saudi Arabia South,Africa Turkey and Vietnam. Source IQVIA,MIDAS May 2018, PHARMACEUTICAL R D EXPENDITURE IN EUROPE USA AND JAPAN MILLION OF NATIONAL CURRENCY. UNITS 1990 2016,33 415 33 949,20 000 14 577,7 766 7 462.
10 000 6 803 5 161,1990 2000 2010 2015 2016, Note Europe million USA million Japan million x 100. Europe USA Japan,Source EFPIA member associations PhRMA JPMA. SHARE OF PARALLEL IMPORTS IN PHARMACY MARKET SALES 2016. 10 8 5 8 2,1 6 1 6 1 9, Austria Belgium Denmark Germany Ireland Netherlands Poland Sweden U K. K in of pharmacy market sales at reimbursement prices. Source EFPIA member associations estimate,EFPIA Key Data 2018. PHARMACEUTICAL INDUSTRY RESEARCH,AND DEVELOPMENT IN EUROPE.
All new medicines introduced into the market are T he cost of researching and developing a new. the result of lengthy costly and risky research and chemical or biological entity was estimated. development R D conducted by pharmaceutical at 1 926 million 2 558 million in year 2013. companies dollars in 2016 DiMasi et al Journal of Health. Economics January 2016, By the time a medicinal product reaches the market. an average of 12 13 years will have elapsed since the n average only one to two of every 10 000. first synthesis of the new active substance substances synthesised in laboratories will. successfully pass all stages of development,required to become a marketable medicine. PHASES OF THE RESEARCH AND DEVELOPMENT PROCESS,nt to y ni. te og i io,ol ty Cl at,Ac ac ici is,Screening 10 000 molecules. Ph a se at en nc,Ph str m ila,e gi e r se i g,R ic bu cov.
1 medicinal product,0 5 years 10 years 15 years 20 years 25 years. patent expiry SPC supplementary protection,certificate max 5 years. 10 years of R D 2 to 3 years of,administrative procedures. PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT IN EUROPE. EFPIA 2016 million million,Austria 294 Latvia n a,Belgium 2 889 Lithuania n a. Bulgaria n a Malta n a,Croatia 40 Netherlands 642,Cyprus 85 Norway 126.
Czech Republic 77 Poland 289,Denmark 1 497 Portugal 75. Estonia n a Romania 109,Finland 198 Russia 412,France 4 451 Slovakia n a. Germany 6 227 Slovenia 180,Greece 42 Spain 1 085,Hungary 178 Sweden 1 104. Iceland n a Switzerland 6 429,Ireland 305 Turkey 66. Italy 1 470 U K 5 679,TOTAL 33 949, The figures relate to the R D carried out in each country.
Austria France Greece Norway Portugal Sweden 2015 data Cyprus Ireland 2013 data Czech Republic 2012 data Croatia. Netherlands 2011 data, Belgium Croatia Denmark France Germany Greece Ireland Italy Netherlands Norway LMI members Poland Romania. Slovenia Sweden LIF members Switzerland Interpharma members Turkey estimate. Source EFPIA member associations official figures,EFPIA Key Data 2018. AllocationOFofR D,ALLOCATION R D investments,INVESTMENTS by function. BY FUNCTION,17 2 Pre human Pre clinical,9 2 Phase I. 11 3 Phase II,Clinical Trials,28 0 Phase III,3 7 Approval.
11 4 Pharmacovigilance Phase IV,Source PhRMA Annual Membership Survey. 19 2 Uncategorized,2017 percentages calculated from 2016. data total values may be affected,by rounding, NUMBER OF NEW CHEMICAL OR BIOLOGICAL ENTITIES 1998 2017. Europe USA Japan Others,1998 2002 2003 2007 2008 2012 2013 2017. Source SCRIP EFPIA calculations according to nationality of mother company. IMPORTANCE OF,PHARMACEUTICAL R D 2 400, In 2016 the pharmaceutical industry invested nearly 2 200.
34 000 million in R D in Europe A decade of strong. US market dominance led to a shift of economic, and research activity towards the US during the 2 000. period 1995 2005 Additionally Europe is now facing 1 900. increasing competition from emerging economies, rapid growth in the market and research environments. in countries such as Brazil and China are contributing 1 700. to the move of economic and research activities to 1 600. non European markets The geographical balance of,the pharmaceutical market and ultimately the R D. base is likely to shift gradually towards emerging 1 400. economies 1 300,ESTIMATED FULL COST OF BRINGING A NEW 1 100. CHEMICAL OR BIOLOGICAL ENTITY TO MARKET,MILLION YEAR 2013.
Source Joseph A DiMasi Henry G Grabowski Ronald W Hansen. Innovation in the pharmaceutical industry New estimates of R D 700. costs Journal of Health Economics 47 2016 20 33,1970 1980 1990 2000s. Pharmaceutical R D expenditure Annual growth rate,early 1980s early 1990s mid 2000s mid 2010s. PHARMACEUTICAL R D EXPENDITURE ANNUAL GROWTH RATE Note USA data relating to period 2013 2016. Source EFPIA PhRMA,7 4 Europe,2003 2007 2008 2012 2013 2017. EFPIA Key Data 2018, According to EUROSTAT data the pharmaceutical According to the 2016 EU Industrial R D Investment. industry is the high technology sector with the highest Scoreboard the pharmaceutical and biotechnology. added value per person employed significantly higher sector amounts to 19 1 of total business R D. than the average value for high tech and manufacturing expenditure worldwide. industries The pharmaceutical industry is also the sector. with the highest ratio of R D investment to net sales. RANKING OF INDUSTRIAL SECTORS BY OVERALL SECTOR R D INTENSITY. R D AS PERCENTAGE OF NET SALES 2016,Pharmaceuticals biotechnology 15 0.
Software computer services 10 6,Technology hardware equipment 8 4. Automobiles parts 5 9,Electronic electrical equipment 4 7. Healthcare equipment services 4 3,General industrials 4 3. All industries 3 8,Industrial engineering 3 6,Leisure goods 3 2. Chemicals 2 9,Aerospace defence 2 8,0 2 4 6 8 10 12 14 16.
Data relate to the top 2 500 companies with registered offices in the EU 590 Japan 356 the US 837 China 327 and the Rest of. the World 390 ranked by total worldwide R D investment with investment in R D above 21 million. Source The 2016 EU Industrial R D Investment Scoreboard European Commission JRC DG RTD. PHARMACEUTICAL PRODUCTION,EFPIA 2016 million million. Austria 2 737 Latvia 120,Belgium 12 821 Lithuania n a. Bulgaria 121 Malta n a,Croatia 615 Netherlands 6 180. Cyprus 180 Norway 745,Czech Republic n a Poland 2 893. Denmark 14 219 Portugal 1 686,Estonia n a Romania 655.
Finland 1 721 Russia 4 228,France 19 040 Slovakia n a. Germany 29 197 Slovenia 1 936,Greece 895 Spain 15 144. Hungary 3 050 Sweden 7 302,Iceland 89 Switzerland 46 280. Ireland 19 305 Turkey 4 439,Italy 30 010 U K 22 445. TOTAL 248 053,All data based on SITC 54, Bulgaria 2015 data Ireland 2014 data Latvia Romania 2013 data Norway 2012 data Cyprus Netherlands 2010 data.
Croatia Denmark France Ireland Italy Netherlands Norway Portugal Slovenia Spain Sweden Switzerland estimate. Bulgaria Croatia Cyprus France Germany Hungary Ireland Latvia Norway Poland Portugal Romania Slovenia veterinary. products excluded,Source EFPIA member associations official figures. Graph 13 remplir,Efpia 2013,EFPIA Key Data 2018,EMPLOYMENT IN THE PHARMACEUTICAL INDUSTRY. EFPIA 2016 Units Units,Austria 14 634 Latvia 1 971. Belgium 35 250 Lithuania 1 220,Bulgaria 10 800 Malta 445. Croatia 6 000 Netherlands 17 900,Cyprus 1 140 Norway 3 800.
Czech Republic 17 900 Poland 30 351,Denmark 26 963 Portugal 7 400. Estonia 380 Romania 30 000,Finland 4 792 Russia n a. France 98 786 Slovakia 3 000,Germany 115 663 Slovenia 9 493. Greece 16 800 Spain 41 102,Hungary 24 800 Sweden 11 012. Iceland n a Switzerland 44 232,Ireland 26 373 Turkey 20 000.
Italy 64 400 U K 61 000,TOTAL 747 607, Croatia Czech Republic Ireland Sweden 2014 data Denmark Lithuania 2013 data Latvia 2012 data Slovakia 2011 data. The research based pharmaceutical industry can play a critical role in restoring Europe to growth and ensuring future competitiveness in an advancing global economy In 2017 it invested an estimated 35 200 million in R amp D in Europe It directly employs some 750 000 people and generates three to four

Related Books